Medigene AG Stock
Medigene AG Stock
There is an upward development for Medigene AG compared to yesterday, with an increase of €0.065 (1.710%).
Currently there is a rather positive sentiment for Medigene AG with 5 Buy predictions and 1 Sell predictions.
With a target price of €8.00 there is potential for a 106.986% increase which would mean more than doubling the current price of €3.87 for Medigene AG.
Our community identified positive and negative aspects for Medigene AG stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Medigene AG stock. On the other hand our users think that "General Risks" could be a problem in the future.
Currently there is a rather positive sentiment for Medigene AG with 5 Buy predictions and 1 Sell predictions.
With a target price of €8.00 there is potential for a 106.986% increase which would mean more than doubling the current price of €3.87 for Medigene AG.
Our community identified positive and negative aspects for Medigene AG stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Medigene AG stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Medigene AG in the next few years
Pros
1
Could be worthwhile Investment >10% per year
1
Innovative
Cons
1
Higher risks for its business
1
Dependend from some customers or products
Performance of Medigene AG vs. its peers
| Security | Change (%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medigene AG | 1.710% | -2.564% | -13.242% | -19.355% | 7.496% | -77.778% | -51.752% |
| Biofrontera AG | -1.920% | -3.512% | -19.444% | -41.935% | -12.709% | -51.667% | 19.287% |
| Formycon AG | -3.190% | -6.006% | 1.623% | 151.406% | 18.113% | 101.610% | 174.899% |
| B.R.A.I.N. Biotechnology Research and Information Network AG | 3.000% | -17.129% | -1.591% | -6.580% | -4.415% | -63.070% | -12.737% |
Comments
Other discussions about Medigene AG Stock
Trading Medigene AG
Trading Medigene AG
News
Medigene AG: Further encouraging results from long-term follow-up of AML patients in DC vaccine trial
Business news for the stock market
Planegg/Martinsried (08.02.2021/16:00) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the
Focus on solid tumors - Discontinuation of MDG1021 development program
Conference call today, 3.00 pm CET (9.00 am ET)
Planegg/Martinsried (28.01.2021) - 28 January 2021. The Executive Management of Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical
Medigene AG: Medigene expands patent protection of its technologies in key markets, the USA and Europe
Planegg/Martinsried (13.01.2021) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, was